Cite
HARVARD Citation
Bilal, J. et al. (2018). A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. Journal of dermatological treatment. pp. 569-578. [Online].